CINECA IRIS Institutional Research Information System

BOTTICI, VALERIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.877
EU - Europa 3.886
AS - Asia 3.612
SA - Sud America 545
AF - Africa 273
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.206
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.686
DE - Germania 1.131
SG - Singapore 1.111
CN - Cina 1.031
IT - Italia 866
SE - Svezia 597
HK - Hong Kong 503
BR - Brasile 432
VN - Vietnam 323
GB - Regno Unito 320
BG - Bulgaria 201
FR - Francia 153
AT - Austria 138
CI - Costa d'Avorio 131
RU - Federazione Russa 131
CA - Canada 128
IN - India 119
TR - Turchia 109
FI - Finlandia 104
JP - Giappone 97
KR - Corea 68
SN - Senegal 65
BD - Bangladesh 45
UA - Ucraina 45
AR - Argentina 39
IQ - Iraq 38
NL - Olanda 36
MA - Marocco 33
MX - Messico 31
PL - Polonia 30
PK - Pakistan 22
ZA - Sudafrica 22
CH - Svizzera 20
BE - Belgio 16
CO - Colombia 16
GR - Grecia 16
UZ - Uzbekistan 16
VE - Venezuela 16
ES - Italia 15
PH - Filippine 15
ID - Indonesia 14
SA - Arabia Saudita 13
CZ - Repubblica Ceca 12
IR - Iran 12
EC - Ecuador 11
AZ - Azerbaigian 10
LT - Lituania 10
AU - Australia 9
IE - Irlanda 9
MY - Malesia 9
CR - Costa Rica 8
IL - Israele 8
JO - Giordania 8
CL - Cile 7
PY - Paraguay 7
TW - Taiwan 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 5
EE - Estonia 5
HU - Ungheria 5
PA - Panama 5
PE - Perù 5
TN - Tunisia 5
AL - Albania 4
BO - Bolivia 4
BY - Bielorussia 4
GT - Guatemala 4
KZ - Kazakistan 4
LB - Libano 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
BH - Bahrain 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EG - Egitto 3
HN - Honduras 3
JM - Giamaica 3
KE - Kenya 3
PS - Palestinian Territory 3
TT - Trinidad e Tobago 3
AO - Angola 2
DK - Danimarca 2
GA - Gabon 2
GE - Georgia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NP - Nepal 2
PT - Portogallo 2
RO - Romania 2
XK - ???statistics.table.value.countryCode.XK??? 2
A1 - Anonimo 1
AI - Anguilla 1
BB - Barbados 1
BZ - Belize 1
ET - Etiopia 1
EU - Europa 1
HR - Croazia 1
LV - Lettonia 1
LY - Libia 1
Totale 15.198
Salva come PNG Salva come JPEG
Città #
Ashburn 823
Singapore 608
Dallas 605
Hong Kong 487
San Jose 438
Woodbridge 419
Chandler 405
Santa Clara 393
Fairfield 387
Ann Arbor 295
Houston 280
Milan 233
Shanghai 211
Beijing 204
New York 202
Sofia 199
Seattle 174
Cambridge 146
Wilmington 143
Los Angeles 132
Abidjan 131
Vienna 125
Munich 115
Boardman 98
Princeton 98
Ho Chi Minh City 94
Lauterbourg 79
Tokyo 77
Florence 76
Frankfurt am Main 76
Lawrence 75
Ottawa 75
Hefei 74
London 73
Pisa 67
Dakar 65
Rome 63
Seoul 57
Serra 55
Medford 53
Council Bluffs 46
Hanoi 45
São Paulo 45
Bremen 44
Jacksonville 43
Dearborn 41
Des Moines 41
Nanjing 41
Boulder 40
Izmir 40
Helsinki 39
Istanbul 39
Buffalo 38
Dong Ket 36
Lancaster 34
Redondo Beach 34
Redwood City 33
Redmond 32
San Diego 28
Orem 25
Fuzhou 24
Turku 24
Casablanca 23
Baghdad 20
Tianjin 20
Warsaw 20
Amsterdam 19
Atlanta 19
Montreal 19
Changsha 18
Denver 18
Phoenix 18
Washington 18
Guangzhou 17
Toronto 17
Belo Horizonte 16
Brussels 16
Ogden 15
San Francisco 15
Boston 14
Brooklyn 14
Tashkent 14
Bengaluru 13
Nanchang 13
Quanzhou 13
Bern 12
Columbus 12
Düsseldorf 12
Nuremberg 12
Rio de Janeiro 12
Chengdu 11
Chicago 11
Dhaka 11
Jiaxing 11
Johannesburg 11
Lucca 11
Mumbai 11
Paris 11
Scandicci 11
Chiesina Uzzanese 10
Totale 9.780
Salva come PNG Salva come JPEG
Nome #
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 289
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 253
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 248
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 244
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 242
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 240
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 234
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 234
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 228
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 226
Targeted Therapy in Thyroid Cancer: State of the Art 224
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 219
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 219
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 217
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 215
RET point mutations in Thyroid Carcinoma 208
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 204
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 203
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 197
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 196
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 193
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 192
Il carcinoma tiroideo: nuove prospettive terapeutiche. 191
DIAGNOSTIC AND THERAPEUTIC ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 191
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 188
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 184
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 179
Ruolo putativo di H4 come gene oncosoppressore nella patogenesi del carcinoma papillare della tiroide 177
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 177
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 177
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 177
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 177
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 177
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 176
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders 176
Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze 174
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 172
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 171
Central Neck Dissection Cannot Be Avoided In Medullary Thyroid Cancer (MTC) On The Basis Of Presurgical Serum Calcitonin (CT) 171
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 170
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 170
RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population 169
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 167
Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer 166
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 164
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 163
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 163
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 162
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 161
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 161
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 161
Prevalenza di mutazioni di BRAF e riarrangiamenti RET/PTC e TRK in una serie di carcinomi papillari della tiroide 160
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 156
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 155
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 155
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 155
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 154
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 154
Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series 151
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 149
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 148
null 146
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 143
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series 142
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 141
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 137
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 136
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 134
Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer 131
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 129
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 129
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib 128
Proteinuria is a late-onset adverse event in patients treated with cabozantinib 128
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 127
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer 125
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 124
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 119
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 117
null 114
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 113
Hypothesizing a role of ret hyperactivation on weight control in patients with type 2A multiple endocrine neoplasia (MEN2A) 110
null 103
Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastasis. 102
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 Years experience at one single center 100
null 99
MULTIFOCALITY AND BILATERALITY IN MEDULLARY THYROID CANCER: BASIS FOR A PROOF-OF-CONCEPT SAFETY OF LOBECTOMY 92
Predictive factors for central neck compartment lymphnodes metastases' in sporadic medullary thyroid cancer patients 89
null 86
Ret Oncogene and Thyroid Carcinoma 81
Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report. 74
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study 71
null 70
null 70
Postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform ¹³¹l ablation 63
Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels. 60
Fifty Years after the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases 54
null 51
Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers 21
Comparison of pre-operative calcitonin, FNAC, and ultrasound risk stratification systems in patients with medullary thyroid carcinoma 20
Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience 15
Totale 15.368
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.308
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.308
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021107 0 0 0 0 0 0 0 0 0 0 0 107
2021/20221.015 37 45 18 69 206 123 39 45 53 47 76 257
2022/20231.721 203 276 139 128 145 186 30 108 358 17 115 16
2023/20241.101 101 105 154 61 130 221 83 36 14 17 62 117
2024/20253.130 18 111 51 206 345 320 254 162 301 391 296 675
2025/20264.162 329 645 436 380 430 304 593 171 261 330 158 125
Totale 15.415